Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCEPT: Vorolanib + Everolimus in mRCC
NCT03095040Phase 3Unknown
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Dec 2016
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vorolanib in renal cell carcinoma (RCC), sponsored by AnewPharma Company, Ltd.. Status: unknown.
02
Drugs
vorolanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03095040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03095040.